Terbium-161 Radioligand Therapy Physics

Introduction

Terbium-161 is, physically, almost a twin of lutetium-177 — nearly the same half-life, a similar medium-energy beta particle, and identical lanthanide chemistry — but it adds a substantial yield of conversion and Auger electrons, and that extra short-range dose is the whole point. For single cells and micrometastases that are smaller than the range of a beta particle, those short-range electrons deposit energy that a beta would carry away, so Tb-161 can out-dose Lu-177 exactly where it matters most.

Lutetium-177 therapies such as Lu-177-DOTATATE and Lu-177-PSMA-617 have made radioligand therapy a mainstream tool. Terbium-161 is the most direct "next-generation" variation on that success: because it shares Lu-177's chemistry and half-life, an established ligand can be relabeled with Tb-161 and run through a comparable radiopharmacy and imaging workflow, while gaining an Auger- and conversion-electron bonus at the cellular scale. ^{1, 2, 3}

This article explains the decay physics that distinguishes Tb-161, how its dosimetry differs at the micrometastatic scale, how it is produced and imaged, and what an emerging Tb-161 program means for radiation safety and licensing. DRPS supports facilities evaluating these programs through its PET/CT and nuclear medicine physics and radioactive material license support services across Florida, Maryland, Virginia, Washington DC, California, and Nevada.

Topic Explanation

What makes terbium-161 interesting

Terbium-161 is a medium-energy beta-minus emitter, with a half-life near 6.89 days and a mean beta energy of about 154 keV, that additionally emits a significant number of conversion and Auger electrons. It is, in effect, Lu-177 plus a dense, short-range electron component. ^{1, 3}

Three features make it attractive for radioligand therapy:

It behaves like Lu-177 chemically. Both are trivalent lanthanides that bind the same DOTA-type chelators, so ligands developed for Lu-177 — PSMA-617, DOTATOC, DOTATATE — can be labeled with Tb-161 without redesigning the molecule. ^{2, 3}
It adds short-range electrons. The conversion and Auger electrons deposit energy over micrometer-to-sub-cellular ranges, raising the dose to the smallest targets. ^{1, 4}
It can be imaged. Tb-161 emits low-energy photons usable for gamma-camera and SPECT/CT imaging, enabling post-therapy dosimetry of the therapeutic agent itself. ⁵

For background on how emission characteristics drive radionuclide selection, see our overview of common PET and radiopharmaceutical-therapy isotopes and the Lu-177 production primer.

Tb-161 and Lu-177 side by side

Property	Lutetium-177	Terbium-161
Physical half-life	About 6.65 days	About 6.89 days
Mean beta energy	About 134 keV	About 154 keV
Extra electron emissions	Minor	Substantial conversion and Auger electrons
Imageable photons	Low-energy gammas (about 113 and 208 keV)	Low-energy photons suitable for SPECT
Chemistry / chelator	Trivalent lanthanide; DOTA-type	Trivalent lanthanide; DOTA-type (same ligands)
Production	Reactor; direct or indirect (n.c.a.) route	Reactor; from enriched Gd-160 targets (n.c.a.)
Dose advantage scale	Comparable at large tumors	Higher at cell-sized and micrometastatic targets

The half-life, chemistry, and imageability are close enough that Tb-161 can slot into an existing Lu-177-style workflow. The emission spectrum is where the clinically meaningful difference lives. ^{1, 2, 3, 6}

Key Technical Principles

Why short-range electrons change the dose to small targets

A beta particle from Lu-177 or Tb-161 travels a sub-millimeter-to-millimeter range in tissue. In a large tumor, most of that energy is absorbed locally. But in a single cell or a micrometastasis a few tens of micrometers across, a large fraction of a beta's energy is carried out of the target before it is deposited — the target is simply smaller than the beta range, so the self-dose is inefficient. ⁴

Conversion and Auger electrons behave differently. Their ranges span micrometers down to less than a single cell diameter, so they deposit their energy inside small targets instead of escaping. Tb-161's extra conversion and Auger yield therefore adds dose precisely at the scale where beta emission is least efficient. ^{1, 4}

Monte Carlo cellular dosimetry makes the effect concrete. Using the CELLDOSE code to compare a uniform distribution of several radionuclides in spheres from 10 mm down to 10 micrometers — normalized so that fully absorbing 1 MeV per cubic micrometer corresponds to 160 Gy — one study reported the following electron doses: ⁴

Target size	Y-90	Lu-177	In-111	Tb-161
10 mm sphere	96.5 Gy	152 Gy	153 Gy	152 Gy
100 µm metastasis	1.36 Gy	24.5 Gy	38.9 Gy	44.5 Gy
10 µm cell	—	3.92 Gy	22.8 Gy	14.1 Gy

At 10 mm, the four radionuclides (except the high-energy Y-90) are essentially equivalent. As the target shrinks, the picture inverts: in a 100 µm metastasis Tb-161 delivers about 44.5 Gy versus 24.5 Gy for Lu-177, and in a 10 µm cell Tb-161 delivers about 14.1 Gy versus 3.92 Gy for Lu-177. The short-range electrons, not the beta, drive that advantage. ⁴

Dosimetry: the MIRD bookkeeping still applies

Tb-161 dosimetry uses the same MIRD framework as any radiopharmaceutical. The mean absorbed dose to a target region is the time-integrated activity (cumulated activity) multiplied by a radionuclide- and geometry-specific S value:

\overline{D} = \tilde{A} \cdot S

The cumulated activity is the integral of activity over time. For mono-exponential clearance it reduces to the administered activity divided by the effective decay constant:

\tilde{A} = \int_{0}^{\infty} A (t) d t = \frac{A _{0}}{λ _{eff}} = \frac{A _{0} T _{eff}}{ln 2}

where the effective half-life combines the physical and biological terms:

\frac{1}{T _{eff}} = \frac{1}{T _{phys}} + \frac{1}{T _{bio}}, λ_{phys} = \frac{ln 2}{T _{phys}} = \frac{0.693}{6.89 d} = 0.101 d^{- 1}

As a worked example, take an administered activity $A_{0} = 7.4 GBq$ and assume long biological retention in the target so that $T_{eff} \approx T_{phys} = 6.89 d = 5.95 \times 1 0^{5} s$ :

\tilde{A} = \frac{A _{0}}{λ _{eff}} = \frac{7.4 \times 1 0 ^{9} Bq}{1.16 \times 1 0 ^{- 6} s ^{- 1}} \approx 6.4 \times 1 0^{15} decays

That cumulated-activity figure is then multiplied by the appropriate S value to obtain the absorbed dose. The crucial point for Tb-161 is that its S value at small scales is larger than Lu-177's because of the extra conversion and Auger energy deposited locally — the same $\tilde{A}$ yields more dose to a cell-sized target. S values and biological half-lives are ligand- and geometry-specific and must be derived from measured biodistribution, not assumed. ^{7, 8}

For the general internal-dosimetry methods behind this, see the MIRD schema for internal dosimetry and radiopharmaceutical dosimetry under ICRP 128.

Production and radiochemistry

Tb-161 is reactor-produced by the indirect route: enriched gadolinium-160 targets are neutron-irradiated, neutron capture forms gadolinium-161, and that beta-decays to terbium-161. The terbium is then isolated from the bulk gadolinium target and from its stable dysprosium decay product by cation-exchange chromatography, yielding no-carrier-added Tb-161 with the high specific activity needed for receptor-targeted ligands. Early development work demonstrated production of therapy-scale quantities and recovery of roughly 80–90 percent of the available Tb-161 at suitable purity; later work confirmed reactor production of therapy-scale no-carrier-added Tb-161 at high radionuclidic purity. ^{1, 3}

Because the finished radiochemistry mirrors Lu-177 labeling, a radiopharmacy already running Lu-177 ligands faces a familiar labeling and quality-control process, with the supply chain for the Gd-160 target and separation being the main new element. ^{1, 2, 3}

Clinical Impact

Where the micrometastatic advantage could matter

The scale-dependent dose advantage points to a clear hypothesis: Tb-161 should help most against minimal residual and micrometastatic disease, where Lu-177's beta is inefficient. Preclinical work supports the direction. A study of Tb-161-PSMA-617 found greater reduction of prostate-tumor-cell viability and survival in vitro than equal activities of Lu-177-PSMA-617, and in tumor-bearing mice Tb-161-PSMA-617 increased median survival in an activity-dependent way (36 days at the lower activity and 65 days at the higher activity, versus 19 days for untreated controls). ²

The theranostic framing is also attractive. A first-in-humans feasibility study administered 596 and 1300 MBq of Tb-161-DOTATOC to two patients with neuroendocrine disease, acquired serial imaging for dosimetry, and produced high-quality SPECT/CT that visualized even small bone and liver metastases, with no related adverse events reported. That established that the therapy isotope can be imaged and tracked directly. ⁵

Evidence maturity and honest caveats

The case for Tb-161 is biologically and dosimetrically compelling but clinically early. The strongest data are cellular dosimetry modeling, in-vitro and animal therapy studies, and first-in-humans imaging feasibility. ^{1, 2, 4, 5} A contemporaneous editorial framed Tb-161 as a promising theranostic radionuclide whose additional high-LET Auger and conversion electrons may improve micrometastatic tumor-cell kill, while emphasizing that ongoing trials and production scale-up are what will determine its clinical role. ⁶

Important open questions remain: how much of the modeled sub-cellular dose advantage translates into clinical benefit, how routine dosimetry should account for Auger contributions, and how supply and standardization will scale. None of this is settled, and Tb-161 is not an approved routine therapy. A facility should treat it as an emerging, investigational agent, not a drop-in upgrade. ⁶

Practical Optimization Tips

For a facility or physicist evaluating a Tb-161 program:

1. Reuse the Lu-177 workflow where you safely can

The shared chemistry and half-life mean labeling, quality control, and imaging resemble an existing Lu-177 program. Map the Tb-161 process against your Lu-177 standard operating procedures and identify only the genuine deltas: target and isotope supply, any labeling-condition differences, and imaging energy-window setup.

2. Set up quantitative SPECT/CT for the therapy isotope

Because Tb-161 is imageable, plan post-therapy SPECT/CT with appropriate low-energy windows and scatter correction so you can perform patient-specific dosimetry. Verify camera calibration and reconstruction against a known source before trusting quantitative numbers. See quantitative SPECT/CT calibration for the underlying method.

3. Build dosimetry on measured biodistribution

Do not import Lu-177 S values or dose coefficients unchanged. The sub-cellular dose component is exactly what differs, so absorbed-dose estimates should use Tb-161-appropriate factors and the patient's measured kinetics. Voxel-level methods are preferable where heterogeneity matters — see voxel-based dosimetry for radiopharmaceutical therapy.

4. Treat it as an emerging use from day one

Plan the license amendment, written procedures, contamination controls, waste management, and staff training before the first dose, the same way you would for any new therapy radionuclide.

Common pitfalls to avoid

Assuming Tb-161 equals Lu-177 dosimetrically. The scale-dependent electron dose is the whole difference; using Lu-177 factors understates small-target dose.
Skipping therapy-isotope imaging. Tb-161 is imageable; not using that forgoes direct dosimetry.
Over-reading early data. Preclinical and feasibility results are promising but not proof of clinical superiority.
Underplanning the supply chain. The Gd-160 target and separation step are the practical bottleneck.
Copying another radionuclide's license conditions. An emerging use needs its own radiation-safety and licensing basis.

Regulatory Considerations

In the United States, a terbium-161 therapy program is medical use of byproduct material and must be licensed and operated under the federal or Agreement State medical-use framework, with procedures documented so the program is defensible during review or inspection. Because Tb-161 has no established authorized-user category of its own, clinical use generally proceeds under the emerging-use provisions.

Key frameworks to reference:

10 CFR Part 20 — Standards for Protection Against Radiation, setting occupational and public dose limits that drive shielding, waste, and release decisions. ⁹
10 CFR Part 35 — Medical Use of Byproduct Material, governing authorized use, written directives, patient release, and the Radiation Safety Officer's responsibilities. ¹⁰
10 CFR 35.1000 — Other Medical Uses, the pathway the NRC uses for emerging therapies that lack a dedicated use category; a Tb-161 program will typically be reviewed under this emerging-use framework with NRC-reviewed guidance. ¹¹
NRC NUREG-1556, Volume 9 — program-specific guidance for medical-use licenses, including expectations for facility design, surveys, and radiation-safety procedures. ¹²
ICRP Publication 107 — nuclear decay data used to characterize emissions for dosimetry and shielding. ¹³

Agreement States administer their own equivalent programs. Of the states DRPS serves, Florida, Maryland, Virginia, California, Nevada, Pennsylvania, New York, and New Jersey are NRC Agreement States that license medical use under their own radiation-control rules, while Washington, DC and Delaware are regulated directly by the NRC. A facility must confirm which authority issues its license and which emerging-use conditions apply before starting. The program should also coordinate shielding and waste review with radioactive material license support and radiation shielding design. For the isotope-specific shielding logic that applies to therapy programs, see RPT shielding for Lu-177, Ra-223, and Ac-225.

Frequently Asked Questions (FAQs)

What is terbium-161?

Terbium-161 (Tb-161) is a therapeutic radionuclide with physical properties very similar to lutetium-177: a half-life of about 6.89 days, a medium-energy beta emission, and lanthanide chemistry that uses the same DOTA-type chelators. Its distinguishing feature is that it also emits a substantial number of conversion and Auger electrons, adding short-range dose that Lu-177 does not provide.

How is Tb-161 different from Lu-177?

Chemically and in half-life the two are nearly interchangeable, so an existing Lu-177 ligand such as PSMA-617 or DOTATOC can be labeled with Tb-161 using the same chelator. The difference is the emission spectrum: Tb-161 co-emits conversion and Auger electrons whose range is sub-cellular, so it deposits more energy per decay in cell-sized and micrometastatic targets than Lu-177 does.

Why do Auger and conversion electrons matter for therapy?

Conversion and Auger electrons have very short ranges, from micrometers down to less than a cell diameter, and deposit energy densely and locally. For single cells and micrometastases that are smaller than the range of a beta particle, much of a beta's energy escapes the target. The short-range electrons of Tb-161 are retained, so the absorbed dose to very small targets is higher.

How is terbium-161 produced?

Tb-161 is produced in a nuclear reactor by neutron irradiation of enriched gadolinium-160 targets. Neutron capture forms gadolinium-161, which beta-decays to terbium-161. The terbium is then separated from the gadolinium target and its stable decay products by ion-exchange chromatography to yield no-carrier-added Tb-161 suitable for high-specific-activity radiolabeling.

Can terbium-161 be imaged?

Yes. Tb-161 emits low-energy photons that can be imaged with a gamma camera and SPECT/CT, so post-therapy imaging and dosimetry of the therapy agent itself are feasible. A first-in-humans study using Tb-161-DOTATOC produced high-quality SPECT/CT images and visualized even small metastases, and the elementally related terbium isotopes offer additional theranostic imaging options.

Does terbium-161 change the radiation-safety picture compared with lutetium-177?

The external photon field is broadly similar to Lu-177, since both emit low-energy photons rather than high-energy gammas, but the two are not identical and every program must base shielding and release decisions on measured dose rates and the specific agent. In the United States, a Tb-161 therapy program is medical use of byproduct material and generally requires licensing as an emerging use, plus contamination control, waste management, and dosimetry procedures.

Is terbium-161 approved for routine clinical use?

As of 2025, terbium-161 radioligand therapy is an emerging, investigational approach. The strongest evidence is preclinical and early-phase, including micrometastasis dosimetry modeling, animal therapy studies, and first-in-humans imaging feasibility. It is not an FDA-approved routine therapy, so use occurs under research and emerging-use frameworks rather than as standard care.

Key Takeaways

Tb-161 is a Lu-177 look-alike with a bonus. Nearly the same half-life and identical chemistry, plus a substantial yield of conversion and Auger electrons.
The advantage is scale-dependent. At large tumors Tb-161 and Lu-177 are comparable; at 100 µm and cell-sized targets, Tb-161 delivers markedly more dose.
Dosimetry needs Tb-161-specific factors. The MIRD framework is unchanged, but the small-scale S value is larger, so Lu-177 numbers understate the dose.
It is imageable. Low-energy photons enable SPECT/CT and direct post-therapy dosimetry.
Production is reactor-based from enriched Gd-160 targets, with chromatographic separation to no-carrier-added product.
It is emerging, not approved. Treat it as an investigational, emerging-use program with its own licensing and radiation-safety basis.

Conclusion

Terbium-161 is one of the clearest examples of how emission physics, not chemistry, can differentiate a therapy radionuclide. By pairing a Lu-177-like beta and half-life with a dense, short-range electron component, it targets exactly the micrometastatic scale where beta therapy is least efficient, while remaining compatible with established ligands, radiopharmacy, and imaging.

The physicist's job is to keep the enthusiasm honest: build dosimetry on Tb-161-appropriate factors and measured kinetics, use the isotope's imageability for patient-specific dose estimates, and license and operate the program as the emerging use it is. Done that way, a Tb-161 program captures the physics advantage without outrunning the evidence.

How DRPS Can Help

Diagnostic Radiation Physics Services helps nuclear medicine and theranostics programs translate radionuclide physics into practical, documented workflows. For an emerging Tb-161 program, that can include dosimetry program design, quantitative SPECT/CT setup, shielding and waste review, survey and contamination-control procedures, staff training support, radioactive material license support, and PET/CT and nuclear medicine physics aligned with NRC and Agreement State requirements.

DRPS supports facilities across our service locations, including Florida, Maryland, Virginia, Washington DC, California, Nevada, New York, Pennsylvania, New Jersey, and Delaware.

A strong theranostics program is built before the first dose arrives — in the dosimetry plan, the procedures, and the license.

Related Resources

References

Lehenberger S, Barkhausen C, Cohrs S, et al. The low-energy β(-) and electron emitter 161Tb as an alternative to 177Lu for targeted radionuclide therapy. Nuclear Medicine and Biology. 2011;38(6):917-924. doi:10.1016/j.nucmedbio.2011.02.007. PubMed
Müller C, Umbricht CA, Gracheva N, et al. Terbium-161 for PSMA-targeted radionuclide therapy of prostate cancer. European Journal of Nuclear Medicine and Molecular Imaging. 2019;46(9):1919-1930. doi:10.1007/s00259-019-04345-0. PubMed
Gracheva N, Müller C, Talip Z, et al. Production and characterization of no-carrier-added 161Tb as an alternative to the clinically-applied 177Lu for radionuclide therapy. EJNMMI Radiopharmacy and Chemistry. 2019;4(1):12. doi:10.1186/s41181-019-0063-6. PubMed
Hindié E, Zanotti-Fregonara P, Quinto MA, Morgat C, Champion C. Dose deposits from 90Y, 177Lu, 111In, and 161Tb in micrometastases of various sizes: implications for radiopharmaceutical therapy. Journal of Nuclear Medicine. 2016;57(5):759-764. doi:10.2967/jnumed.115.170423. PubMed
Baum RP, Singh A, Kulkarni HR, et al. First-in-humans application of 161Tb: a feasibility study using 161Tb-DOTATOC. Journal of Nuclear Medicine. 2021;62(10):1391-1397. doi:10.2967/jnumed.120.258376. PubMed
Liang SH. From lutetium to terbium: a new era in PSMA-targeted radioligand therapy for mCRPC patients. American Journal of Nuclear Medicine and Molecular Imaging. 2025;15(5):219-222. doi:10.62347/JAXA6254. PubMed
Bolch WE, Eckerman KF, Sgouros G, Thomas SR. MIRD pamphlet No. 21: a generalized schema for radiopharmaceutical dosimetry — standardization of nomenclature. Journal of Nuclear Medicine. 2009;50(3):477-484. doi:10.2967/jnumed.108.056036. PubMed
International Commission on Radiological Protection. ICRP Publication 128: Radiation Dose to Patients from Radiopharmaceuticals. Annals of the ICRP. 2015;44(2S). icrp.org
U.S. Nuclear Regulatory Commission. 10 CFR Part 20: Standards for Protection Against Radiation. ecfr.gov
U.S. Nuclear Regulatory Commission. 10 CFR Part 35: Medical Use of Byproduct Material. ecfr.gov
U.S. Nuclear Regulatory Commission. 10 CFR 35.1000: Other Medical Uses of Byproduct Material or Radiation from Byproduct Material. ecfr.gov
U.S. Nuclear Regulatory Commission. NUREG-1556, Volume 9, Revision 3: Program-Specific Guidance About Medical Use Licenses. nrc.gov
International Commission on Radiological Protection. ICRP Publication 107: Nuclear Decay Data for Dosimetric Calculations. Annals of the ICRP. 2008;38(3). icrp.org